Cumberland Pharmaceuticals Inc.
CPIX
$2.75
-$0.05-1.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.55M | 8.29M | 10.84M | 11.71M | 9.11M |
| Total Other Revenue | 4.13M | -- | -- | -- | 1.33M |
| Total Revenue | 13.68M | 8.29M | 10.84M | 11.71M | 10.44M |
| Cost of Revenue | 2.24M | 988.80K | 2.01M | 1.43M | 1.98M |
| Gross Profit | 11.44M | 7.30M | 8.83M | 10.29M | 8.46M |
| SG&A Expenses | 10.25M | 7.01M | 7.10M | 6.70M | 7.55M |
| Depreciation & Amortization | 1.01M | 1.01M | 1.01M | 1.01M | 1.46M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.05M | 10.26M | 11.58M | 10.42M | 12.28M |
| Operating Income | -1.37M | -1.97M | -747.50K | 1.29M | -1.84M |
| Income Before Tax | -1.41M | -1.94M | -729.50K | 1.25M | -1.96M |
| Income Tax Expenses | 23.20K | 5.70K | 5.70K | 5.70K | -57.00K |
| Earnings from Continuing Operations | -1.43M | -1.95M | -735.20K | 1.25M | -1.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 17.00K | 8.30K | -5.50K | 8.90K | -2.20K |
| Net Income | -1.41M | -1.94M | -740.70K | 1.26M | -1.90M |
| EBIT | -1.37M | -1.97M | -747.50K | 1.29M | -1.84M |
| EBITDA | -329.30K | -927.50K | 286.40K | 2.32M | -345.60K |
| EPS Basic | -0.09 | -0.13 | -0.05 | 0.08 | -0.14 |
| Normalized Basic EPS | -0.06 | -0.08 | -0.03 | 0.05 | -0.09 |
| EPS Diluted | -0.09 | -0.13 | -0.05 | 0.08 | -0.14 |
| Normalized Diluted EPS | -0.06 | -0.08 | -0.03 | 0.05 | -0.09 |
| Average Basic Shares Outstanding | 14.96M | 14.96M | 14.96M | 14.94M | 13.97M |
| Average Diluted Shares Outstanding | 14.96M | 14.96M | 14.96M | 15.26M | 13.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |